注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Connect Biopharma Holdings Ltd是一家臨床階段的生物製藥公司。該公司致力於開發治療T細胞驅動的炎症性疾病的療法。該公司的主要候選產品CBP-201是一種針對白細胞介素-4受體α(IL-4Ra)的抗體,正在開髮用於治療特應性皮炎和哮喘。其第二個候選產品CBP-307是S1P1 T細胞受體的調節劑,正在開髮用於治療潰瘍性結腸炎(UC)。該公司的第三個候選產品CBP-174是組胺受體3的外周作用拮抗劑,正在開髮用於治療與特應性皮炎(AD)相關的瘙癢症。該公司在美國、中國、歐洲和澳大利亞開展臨床開發活動,並在這些地區以及中國香港開展業務。其子公司包括Connect Biopharma HongKong Limited、Connect Biopharm LLC等。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Stuart J. Swiedler | 67 | 2021 | Member of Scientific Advisory Board |
Edward M. Kerwin | - | 2021 | Member of Scientific Advisory Board |
Zheng Wei | 60 | 2012 | Co-Founder, CEO & Director |
Kleanthis G. Xanthopoulos | 66 | 2020 | Lead Independent Director |
Jean I. Liu | 56 | 2021 | Independent Director |
Kan Chen | 42 | 2020 | Independent Non-Executive Director |
Brian Gordon Feagan | - | 2021 | Member of Scientific Advisory Board |
David T. Rubin | - | 2021 | Member of Scientific Advisory Board |
Karen J. Wilson | 61 | 2020 | Independent Non-Executive Director |
John V. Fahy | - | 2021 | Member of Scientific Advisory Board |
Zuie-Chin Huang | 58 | 2024 | Independent Director |
Jonathan Silverberg | - | 2023 | Member of Scientific Advisory Board |
Emma Guttman-Yassky | - | 2021 | Member of Scientific Advisory Board |
Wubin Pan | 59 | 2012 | Co-Founder, President & Chairman of the Board of Directors |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核